Eiger BioPharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eiger BioPharmaceuticals, Inc.
Creating Best In Class Antivirals In Post-COVID China: Interview with Huahui Health CSO Li Wenhui
COVID-19 has highlighted the need for potent, safe and effective antiviral therapies for infectious diseases and now one well-known Chinese researcher is tackling hepatitis B and D though a homegrown drug discovery approach. He talks to Scrip in this wide-ranging audio interview.
Orphans Account For More Than A Third Of EU New Drug Approvals In 2022
Last year, the European Commission approved a record 55 therapies containing a new active substance, including 21 medicines for rare diseases. Among them were a number of gene therapies for indications such as cancer and hemophilia.
Stock Watch: Filling In The Blanks In Clinical Trial Result Announcements
If a clinical trial is positive, with safety and efficacy that trounces the competition, why be coy about the details?
COVID-19 DNA Vaccine Halt Another Blow To AnGes
AnGes has terminated R&D work on a DNA vaccine for COVID-19 and will now look at intranasal candidates with a US partner. Although the original project received funding from the Japanese government, a spike in related costs caused the Japanese firm's net loss to triple last year, and the decision represents the latest in a string of pipeline setbacks.
- Other Names / Subsidiaries
- Celladon Corporation
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.